BR0108041A - Nova forma galênica oral de liberação prolongada da molsidomina - Google Patents
Nova forma galênica oral de liberação prolongada da molsidominaInfo
- Publication number
- BR0108041A BR0108041A BR0108041-5A BR0108041A BR0108041A BR 0108041 A BR0108041 A BR 0108041A BR 0108041 A BR0108041 A BR 0108041A BR 0108041 A BR0108041 A BR 0108041A
- Authority
- BR
- Brazil
- Prior art keywords
- molsidomine
- hours
- released
- angina
- prolonged release
- Prior art date
Links
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 title abstract 11
- 229960004027 molsidomine Drugs 0.000 title abstract 11
- 230000002035 prolonged effect Effects 0.000 title abstract 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract 4
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001148 spastic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"NOVA FORMA GALêNICA ORAL DE LIBERAçãO PROLONGADA DA MOLSIDOMINA". A presente invenção se refere a uma nova forma galênica oral de liberação prolongada da molsidomina destinada ao tratamento da crise anginosa sob todas as suas formas (angina de esforço, angina espástica, angina mista). Segundo a invenção, esta nova forma galênica contém uma quantidade terapeuticamente eficaz de molsidomina ou de um de seus metabólicos ativos e no que ela apresenta uma taxa de dissolução in vitro [medida espectrofotometricamente a 286 ou 311nm segundo o método descrito na Pharmacopée Européenne, 3<a> edição (ou U.S.P. XXIV) a 50 t.p.m em 500ml de um meio HC1 0,1 N, a 37 <198>C]de: - 15 a 25% de molsidomina liberada após 1 hora - 20 a 35% de molsidomina liberada após 2 horas - 50 a 65% de molsidomina liberada após 6 horas - 75 a 95% de molsidomina liberada após 12 horas - >85% de molsidomina liberada após 18 horas - >90% de molsidomina liberada após 24 horas O pico plasmático de molsidomina obtido in vivo se apresentando nas 2 horas e meia a 5 horas, de preferência nas 3 a 4 horas, seguindo a administração da citada forma e tendo um valor compreendido entre 25 e 40ng/ml de plasma. Aplicação: Indústria terapêutica
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0002307A FR2805462B1 (fr) | 2000-02-24 | 2000-02-24 | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
| PCT/EP2001/002055 WO2001062256A1 (fr) | 2000-02-24 | 2001-02-22 | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0108041A true BR0108041A (pt) | 2002-10-29 |
| BR0108041B1 BR0108041B1 (pt) | 2013-06-18 |
| BRPI0108041B8 BRPI0108041B8 (pt) | 2021-05-25 |
Family
ID=8847342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0108041A BRPI0108041B8 (pt) | 2000-02-24 | 2001-02-22 | nova forma galênica oral de liberação prolongada da molsidomina. |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US7767227B2 (pt) |
| EP (1) | EP1265614B1 (pt) |
| JP (1) | JP4945043B2 (pt) |
| KR (1) | KR100814191B1 (pt) |
| CN (1) | CN100396284C (pt) |
| AT (1) | ATE296632T1 (pt) |
| AU (2) | AU4065301A (pt) |
| BE (1) | BE1013487A3 (pt) |
| BG (1) | BG66111B1 (pt) |
| BR (1) | BRPI0108041B8 (pt) |
| CA (1) | CA2400886C (pt) |
| CZ (1) | CZ301993B6 (pt) |
| DE (1) | DE60111196T2 (pt) |
| DZ (1) | DZ3273A1 (pt) |
| EE (1) | EE05098B1 (pt) |
| ES (1) | ES2241803T3 (pt) |
| FR (1) | FR2805462B1 (pt) |
| HK (1) | HK1050138B (pt) |
| HR (1) | HRP20020692B1 (pt) |
| HU (1) | HU229799B1 (pt) |
| IL (2) | IL151205A0 (pt) |
| IS (1) | IS2446B (pt) |
| MA (1) | MA25576A1 (pt) |
| MD (1) | MD3119C2 (pt) |
| MX (1) | MXPA02008262A (pt) |
| NO (1) | NO329495B1 (pt) |
| NZ (1) | NZ520691A (pt) |
| OA (1) | OA12183A (pt) |
| PL (1) | PL201631B1 (pt) |
| PT (1) | PT1265614E (pt) |
| RS (1) | RS50291B (pt) |
| RU (1) | RU2263506C2 (pt) |
| SK (1) | SK286313B6 (pt) |
| UA (1) | UA73972C2 (pt) |
| WO (1) | WO2001062256A1 (pt) |
| ZA (1) | ZA200206042B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805462B1 (fr) * | 2000-02-24 | 2003-08-15 | Therabel Res | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
| US7803402B2 (en) * | 2002-07-06 | 2010-09-28 | Sanjeev Khandelwal | Pharmaceutical preparations |
| FR2868314B1 (fr) * | 2004-04-05 | 2008-10-24 | Therabel Pharmaceuticals Ltd | Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables |
| EP2468269A1 (en) | 2010-11-26 | 2012-06-27 | Universitätsklinikum Münster | Nitric oxide donors in therapy of nitric oxide deficiency-induced disturbances of cerebral microcirculation |
| BE1028879B1 (fr) | 2020-12-11 | 2022-07-12 | Europharmaceuticals | Comprimé à libération prolongée de la molsidomine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3522191A1 (de) * | 1985-06-21 | 1987-01-15 | Cassella Ag | Photostabilisierung von sydnoniminen |
| CN1006522B (zh) * | 1986-04-30 | 1990-01-24 | 田道制药有限公司 | 缓放性制剂的制备方法 |
| HU210921B (en) * | 1990-03-28 | 1995-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them |
| HU211648A9 (en) * | 1990-03-28 | 1995-12-28 | Chinoin Gyogyszer Es Vegyeszet | Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same |
| DE4140192C2 (de) * | 1991-12-05 | 1996-02-29 | Alfatec Pharma Gmbh | Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen |
| ATE185273T1 (de) * | 1993-05-11 | 1999-10-15 | Hoechst Ag | Galenische zubereitungen von molsidomin |
| JPH09503997A (ja) * | 1993-07-08 | 1997-04-22 | シグナス，インコーポレイテッド | モノリシックなマトリックス経皮送達システム |
| IT1266565B1 (it) * | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
| HU218280B (en) * | 1994-04-26 | 2000-07-28 | Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes | |
| DE4443105C2 (de) * | 1994-12-03 | 1997-03-13 | Hoechst Ag | Verfahren zur Herstellung Molsidomin-haltiger Tabletten |
| JPH09114680A (ja) * | 1995-10-19 | 1997-05-02 | Fuji Xerox Co Ltd | シーケンス制御装置 |
| IT1282576B1 (it) * | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
| PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
| AU9496798A (en) * | 1997-09-19 | 1999-04-05 | Shire Laboratories, Inc. | Solid solution beadlet |
| FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| FR2805462B1 (fr) * | 2000-02-24 | 2003-08-15 | Therabel Res | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
-
2000
- 2000-02-24 FR FR0002307A patent/FR2805462B1/fr not_active Expired - Lifetime
-
2001
- 2001-02-22 JP JP2001561321A patent/JP4945043B2/ja not_active Expired - Lifetime
- 2001-02-22 IL IL15120501A patent/IL151205A0/xx active IP Right Grant
- 2001-02-22 EP EP01911692A patent/EP1265614B1/fr not_active Expired - Lifetime
- 2001-02-22 ES ES01911692T patent/ES2241803T3/es not_active Expired - Lifetime
- 2001-02-22 SK SK1220-2002A patent/SK286313B6/sk not_active IP Right Cessation
- 2001-02-22 BR BRPI0108041A patent/BRPI0108041B8/pt not_active IP Right Cessation
- 2001-02-22 US US10/182,718 patent/US7767227B2/en not_active Expired - Fee Related
- 2001-02-22 AU AU4065301A patent/AU4065301A/xx active Pending
- 2001-02-22 OA OA1200200258A patent/OA12183A/fr unknown
- 2001-02-22 CA CA2400886A patent/CA2400886C/fr not_active Expired - Lifetime
- 2001-02-22 WO PCT/EP2001/002055 patent/WO2001062256A1/fr active IP Right Grant
- 2001-02-22 AT AT01911692T patent/ATE296632T1/de active
- 2001-02-22 DE DE60111196T patent/DE60111196T2/de not_active Expired - Lifetime
- 2001-02-22 CZ CZ20022876A patent/CZ301993B6/cs not_active IP Right Cessation
- 2001-02-22 CN CNB018052592A patent/CN100396284C/zh not_active Expired - Lifetime
- 2001-02-22 RU RU2002121503/15A patent/RU2263506C2/ru active
- 2001-02-22 RS YUP-622/02A patent/RS50291B/sr unknown
- 2001-02-22 DZ DZ013273A patent/DZ3273A1/fr active
- 2001-02-22 UA UA2002086983A patent/UA73972C2/uk unknown
- 2001-02-22 NZ NZ520691A patent/NZ520691A/en not_active IP Right Cessation
- 2001-02-22 AU AU2001240653A patent/AU2001240653B9/en not_active Expired
- 2001-02-22 MD MDA20020212A patent/MD3119C2/ro active IP Right Grant
- 2001-02-22 PL PL357550A patent/PL201631B1/pl unknown
- 2001-02-22 HU HU0300607A patent/HU229799B1/hu unknown
- 2001-02-22 KR KR1020027010441A patent/KR100814191B1/ko active IP Right Grant
- 2001-02-22 EE EEP200200472A patent/EE05098B1/xx unknown
- 2001-02-22 BE BE2001/0121A patent/BE1013487A3/fr not_active IP Right Cessation
- 2001-02-22 PT PT01911692T patent/PT1265614E/pt unknown
- 2001-02-22 MX MXPA02008262A patent/MXPA02008262A/es active IP Right Grant
-
2002
- 2002-07-29 ZA ZA200206042A patent/ZA200206042B/xx unknown
- 2002-08-06 MA MA26765A patent/MA25576A1/fr unknown
- 2002-08-12 IL IL151205A patent/IL151205A/en unknown
- 2002-08-14 IS IS6504A patent/IS2446B/is unknown
- 2002-08-22 HR HR20020692A patent/HRP20020692B1/xx not_active IP Right Cessation
- 2002-08-22 BG BG107027A patent/BG66111B1/bg unknown
- 2002-08-23 NO NO20024043A patent/NO329495B1/no not_active IP Right Cessation
-
2003
- 2003-03-27 HK HK03102218.9A patent/HK1050138B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0301452A2 (hu) | Fotokemoterápiás szert és mukoadhéziós szert tartalmazó gyógyszerkészítmény és alkalmazása | |
| HUP0302881A2 (hu) | Legalább egy D-vitamint vagy D-vitamin analóg vegyületet és legalább egy kortikoszteroidot tartalmazó külsőleges gyógyszerkészítmények | |
| HUP0301868A2 (hu) | Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz | |
| WO2008061226A3 (en) | Sustained-release formulations of topiramate | |
| HUP0302131A2 (hu) | Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények | |
| BR0109779A (pt) | Soluções moleculares hidrofìlicas dispersas de carvedilol | |
| CY1110906T1 (el) | Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης | |
| AR040709A1 (es) | Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion | |
| BR9810520A (pt) | Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial | |
| BR0312728A (pt) | Formulação em tablete dispersìvel e processo para sua preparação | |
| BR0306928A (pt) | Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace) | |
| ECSP045493A (es) | Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a | |
| EE05054B1 (et) | 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis | |
| PT1425005E (pt) | Composicao farmaceutica que compreende lumiracoxib | |
| HUP0203295A2 (hu) | Emphysema kezelése RAR-szelektív retinoid agonistákat tartalmazó gyógyszerkészítmények felhasználásával | |
| BR0108041A (pt) | Nova forma galênica oral de liberação prolongada da molsidomina | |
| AR001765A1 (es) | Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales | |
| BR0206819A (pt) | Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca | |
| WO2007010501A3 (en) | A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor | |
| AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida | |
| GB9930075D0 (en) | Medicaments | |
| AR042199A1 (es) | Composicion farmaceutica liquida que comprende una cantidad terapeuticamente eficaz de al menos un compuesto de 3,7 diazabiciclo (3,3,1) nonano, metodo de tratamiento y/o profilaxis de eventos anti-arritmicos en seres humanos y producto y/o forma de presentacion farmaceutica | |
| WO2002053099A3 (en) | Methods and compositions for treating periodontal disease | |
| WO2003101462A3 (en) | Use of bisphosphonic acid derivatives for the treatment of calcium phrophosphated deposition disease and dental treatment | |
| PT1490049E (pt) | Citalopram para o tratamento da pre3ssao sanguinia elevada. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] |
Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/02/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 22/02/2021 |